Specialty life sciences Company
PharmaTher Inc. (CSE: PHRM, Forum) announced on Wednesday that it had entered into an exclusive research collaboration agreement with
Revive Therapeutics Ltd. (CSE: RVV, Forum) to develop psilocybin therapies to treat cancer and to discover novel uses of undisclosed psychedelic compounds, via PHRM’s Artificial Intelligence platform panaceAI.
PharmaTher’s Chief Executive Officer Fabio Chianelli called this collaboration a means to unlock the potential novel uses of psychedelic compounds in diseases that have sub-optimal or no treatment options.
“We have been focused on advancing the clinical development of ketamine in the treatment of Parkinson’s disease, while also discovering novel uses of psychedelics using panaceAI with the aim to partner these developments. The partnership with Revive allows us to focus on expanding our ketamine programs such as the combination of ketamine with an FDA approved drug and the delivery of ketamine via our proprietary microneedle delivery technology targeting large market opportunities in depression, post-operative and neuropathic pain and disorders of the brain and nervous system.”
To read this news in full, click
here.
PharmaTher’s proprietary drug repurposing artificial intelligence platform panaceAI recently discovered the potential novel use of psilocybin
to treat cancer and the Company quickly filed a US provisional patent application.
FULL DISCLOSURE: PharmaTher Inc. and Revive Therapeutics Ltd. are clients of Stockhouse Publishing.